<DOC>
	<DOCNO>NCT02717624</DOCNO>
	<brief_summary>To characterize safety profile acalabrutinib combination bendamustine rituximab subject treatment naive relapse/refractory Mantle Cell Lymphoma ( MCL )</brief_summary>
	<brief_title>A Study Acalabrutinib ( ACP-196 ) Combination With Bendamustine Rituximab Subjects With Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Men woman ≥ 18 year age . Pathologically confirm MCL . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Agreement use highly effective form contraception study 90 day last dose ACP 196 , 120 day last dose bendamustine , 12 month last dose rituximab , whichever long . Treatment Naive MCL patient require treatment exposure prior therapy . Relapsed/Refractory patient define disease relapse refractory ≥ 1 prior therapy MCL require treatment . Patient discontinue prior treatment MCL tolerability reason also enrol . Significant cardiovascular disease uncontrolled untreated symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen , Class 3 4 cardiac disease define New York Heart Association Functional Classification.Exception : Subjects control , asymptomatic atrial fibrillation screening allow enroll study Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach , extensive small bowel resection likely affect absorption , symptomatic inflammatory bowel disease , partial complete bowel obstruction , gastric restriction bariatric surgery , gastric bypass Uncontrolled active systemic fungal , bacterial , viral , infection ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) , intravenous antiinfective treatment within 2 week first dose study drug Breastfeeding pregnant Concurrent participation another therapeutic clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bruton tyrosine kinase inhibitor</keyword>
	<keyword>Btk</keyword>
	<keyword>ACP-196</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>MCL</keyword>
	<keyword>acalabrutinib</keyword>
	<keyword>ACE-LY-106</keyword>
</DOC>